舒血宁注射液联合卡托普利治疗原发性高血压急症患者的临床效果  

Clinical Effect of Shuxuening Injection Combined with Captopril in the Treatment of Patients with Essential Hypertension Emergency

作　　者：李欣[1] LI Xin(Heilongjiang Provincial Hospital,Harbin 150001,China)

机构地区：[1]黑龙江省医院,黑龙江哈尔滨150001

出　　处：《中外医学研究》2024年第31期106-110,共5页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探讨舒血宁注射液联合卡托普利治疗原发性高血压急症患者的临床效果。方法:选择2022年3月—2023年5月黑龙江省医院收治的82例原发性高血压急症患者作为研究对象,按随机分配原则将患者为对照组和观察组,各41例。对照组给予卡托普利治疗,观察组在对照组基础上联用舒血宁注射液,比较两组临床疗效、血压、血清血管内皮细胞功能指标、不良反应及生活质量。结果:观察组总有效率为92.68%,高于对照组的70.73%,差异有统计学意义(P<0.05);治疗后,两组收缩压、舒张压降低,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组血管内皮素-1(ET-1)水平下降,一氧化氮(NO)水平上升,且观察组ET-1水平低于对照组,NO水平高于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率为4.88%,低于对照组的19.51%,差异有统计学意义(P<0.05);治疗后,两组生活质量(QOL)评分升高,且观察组高于对照组,差异有统计学意义(P<0.05)。结论:原发性高血压急症患者应用舒血宁注射液联合卡托普利能提高临床效果,降低血压,改善血清血管内皮功能指标,减少不良反应,提高生活质量。Objective:To investigate the clinical effect of Shuxuening Injection combined with Captopril in the treatment of patients with essential hypertension emergency.Method:A total of 82 patients with essential hypertension emergency who admitted to Heilongjiang Provincial Hospital from March 2022 to May 2023 were selected as the research objects,the patients were divided into the control group and the observation group according to the principle of random distribution,41 cases in each group.The control group was treated with Captopril,while the observation group was treated with Shuxuening Injection on the basis of the control group.The clinical efficacy,blood pressure,serum vascular endothelial function indexes,adverse reactions and quality of life were compared between two groups.Result:The total effective rate of the observation group was 92.68%,which was higher than 70.73%of the control group,and the difference was statistically significant(P<0.05);after treatment,the systolic blood pressure and diastolic blood pressure of two groups were decreased,and those in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05);after treatment,the levels of endothelin-1(ET-1)in two groups were decreased,and the levels of nitric oxide(NO)were increased,the level of ET-1 in the observation group was lower than that in the control group,and the level of NO was higher than that in the control group,the differences were statistically significant(P<0.05);the incidence of adverse reactions in the observation group was 4.88%,which was lower than 19.51%in the control group,the difference was statistically significant(P<0.05);after treatment,the quality of life(QOL)score of two groups were increased,and those of the observation group was higher than those of the control group,the differences were statistically significant(P<0.05).Conclusion:The application of Shuxuening Injection combined with Captopril in patients with essential hypertension emergency can improve clinical

关 键 词：舒血宁注射液 卡托普利 原发性高血压急症 血清血管内皮功能 

分 类 号：R544.11[医药卫生—心血管疾病]